Delivery Order SPE2DB24D1104-SPE2DB25FYEU2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 40 mg capsules (100-count) valued at $2,057.66. The contract, which closed on August 28, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be fulfilled from the contractor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 70 mg capsules (90-count units) with a ceiling value of $1,171.95. This is a firm fixed-price delivery order issued under a competitive procurement with no set-aside designation. The contract was awarded on August 22, 2025, with an ultimate completion date of August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 50 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $5,818.24. This competitively awarded, non-set-aside delivery order was issued on September 23, 2025, with an ultimate completion date of September 24, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,977.61 to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 30 mg capsules (100 count) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price delivery order was issued under a child contract arrangement with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 50 mg capsules (90-unit package) valued at $2,510.96. This competitively awarded, firm fixed-price delivery order was issued on September 4, 2025, with an ultimate completion date of September 5, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,025.65 to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 30 mg capsules (100-count units). The contract was competitively awarded without set-aside provisions and is priced on a firm fixed-price basis, with an ultimate completion date of September 24, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 60 mg capsules (90-count) on September 23, 2025, with a ceiling value of $1,073.09 and an ultimate completion date of September 24, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is the vendor's...
- The Defense Logistics Agency awarded a delivery order valued at $6,698.50 to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 50 mg capsules (100 count units) under a firm fixed price contract type. The award was issued on July 16, 2025, with an ultimate completion date of July 17, 2025, and represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $2,136.69. The award, effective September 2, 2025, with an ultimate completion date of September 3, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 50 mg capsules (100-count units) with a ceiling value of $1,141.26. This competitively awarded, non-set-aside contract is classified as a firm fixed price delivery order with an ultimate completion date of September 17, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYEU2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 50 mg capsules (100 count) with a ceiling value of $6,451.66. The contract was awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, under a firm fixed-price delivery order arrangement. No set-aside designation was utilized in this competitive procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999 million through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen serves the Defense Health Agency and military healthcare systems with a comprehensive range of medications, vaccines, and medical supplies. The company's extensive federal contract portfolio with DLA reflects its established capability to fulfill specialized pharmaceutical requirements across multiple therapeutic domains for military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.5k | 8/20/25 |